2023年5月29日

新澤西州普林斯頓| 2023年5月29日東部時間上午10:30 Longevica,新澤西由科學推動公司致力於揭露延長壽命的機製,積極尋求資金支持其開創性的研究。專用的一個科學家小組和慈善家,Longevica依靠科學數據來源於基本實驗和綜合模型來驅動它的使命。成立於2009年,Longevica的遠景是減緩衰老,推遲衰老相關疾病,並最終消除它們。Longevica的研究采用反向的方法旨在確定延長壽命的機製。公司開始著手一項雄心勃勃的涉及最大的一係列化合物良好的藥理實驗小鼠,使其成為最大的研究長壽的老鼠。研究在加州著名的傑克遜實驗室進行的,涉及20000年長壽的雌性老鼠的影響並分析了1033年藥物化合物,例如鎂、阿司匹林等。據該公司介紹,實驗證明是一場徹底的勝利。此外,通過廣泛的大數據分析,Longevica識別兩個特定類的化合物的共有62家與延長壽命,體現出統計上顯著相關。這一突破提供至關重要的見解機製延長壽命的存在。建築在這些非凡的發現,Longevica團隊專門隨後六年的研究這兩個化合物類。 Their research focused on understanding the mechanisms of action and the historical applications of these compounds in human medicine. As a result, the team in 2019-2021 established valid hypotheses regarding two mechanisms of life extension, with further details currently being specified. Both mechanisms aim to combat harmful compounds accumulation, leading to improved health and extended lifespan. These results were a surprise to all that were part of this experiment, truly showing the lack of knowledge and expectations we have regarding evolution and length of lifespan. The core paradigm of Longevica's life extension approach revolves around reducing “toxins”, thereby mitigating age-related diseases and promoting longevity. Following 14 years of research including their mice experiment and 15 million dollars in financing, Longevica is now poised to complete its aging research. “The truth is that we as humanity have a mission. After years of research, we still don’t understand the mechanisms that would enable us to move the survival curve to the right, meaning extending life span, even in mice. This research will be able to answer many if not all questions regarding life extension, bringing it out of a world of myth into reality. We plan on being able to turn our focus towards human life extension in our future research.” says Alexander Chikunov, founder of Longevica who provided all funds for this stage of research. Media contact: